Mount Yale Investment Advisors, LLC Neurocrine Biosciences Inc Transaction History

Mount Yale Investment Advisors, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$94.11 - $123.02 $67,853 - $88,697	-721 Reduced 11.08%	5,787 $585,000
Q4 2022 Feb 13, 2023	SELL	$106.72 - $127.06 $157,412 - $187,413	-1,475 Reduced 18.48%	6,508 $777,000
Q3 2022 Nov 07, 2022	SELL	$92.03 - $107.81 $19,786 - $23,179	-215 Reduced 2.62%	7,983 $848,000
Q2 2022 Aug 02, 2022	SELL	$75.79 - $100.07 $36,682 - $48,433	-484 Reduced 5.57%	8,198 $799,000
Q1 2022 May 03, 2022	BUY	$72.45 - $94.81 $629,010 - $823,140	8,682 New	8,682 $814,000
Q4 2021 Feb 02, 2022	SELL	$79.65 - $106.22 $520,273 - $693,829	-6,532 Closed	0 $0
Q3 2021 Nov 02, 2021	BUY	$86.18 - $99.03 $4,136 - $4,753	48 Added 0.74%	6,532 $626,000
Q2 2021 Aug 04, 2021	BUY	$89.43 - $102.27 $11,089 - $12,681	124 Added 1.95%	6,484 $631,000
Q1 2021 May 04, 2021	BUY	$87.57 - $119.4 $556,945 - $759,384	6,360 New	6,360 $619,000
Q4 2020 Feb 12, 2021	SELL	$86.91 - $108.33 $441,502 - $550,316	-5,080 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$96.16 - $135.15 $488,492 - $686,562	5,080 New	5,080 $488,000

626

94M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Mount Yale Investment Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Mount Yale Investment Advisors, LLC with notifications on news.